News We’re Watching: Cancer Screening Partnership, New Abbott Electrophysiology Head, V-Champs AI Challenge
This week, Bioventus announced plans to sell its wound business; Pfizer and Thermo Fisher Scientific partnered to increase cancer screening access; and the FDA expanded the magnetic resonance imaging labeling for Abbott’s Eterna spinal cord stimulator.
You may also be interested in...
News We’re Watching: V-Champs Winners Named, Recalls for Fresenius Infusion Pumps and GE Vents, FCC Updates Rural Telehealth Rule
This week, the FDA announced that a new eStar form for 510(k)s will be available in February; Fresenius infusion pumps were recalled due to mechanical issues; and an FCC final rule encouraged the use of telehealth.
The White House Office of Science and Technology Policy has released an updated national strategic framework outlining priorities and goals for federal investment in AI. Industry executive Peter Shen weighs in on the plan.
The approval, supported by the results of the randomized DISTINCT trial, includes all of Abbott’s spinal cord stimulation devices that deliver the proprietary BurstDR waveform.